L1-blocking antibody is now approved for metastatic or locally advanced cutaneous SCC in adults who are not candidates for curative surgery or curative radiation.

In a subset of patients in a 48-week extension trial, the mean duration of the first treatment-free interval was ...

Robert F. Kennedy Jr., Trump's pick for HHS secretary, could use his powers at the FDA to go after facilities abroad and ...

Part of the joy of the season may be gone — or feel different — for people who are taking popular weight-loss drugs and can't ...

The FDA is warning it found undeclared prescription drugs in men's supplements used to enhance energy and sexual performance.